Establishment Labs Notes Presentation Of 4-Year Results From Motiva U.S. IDE Study At The Aesthetic Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Establishment Labs Holdings Inc. (NASDAQ:ESTA) announced the presentation of four-year results from the Motiva US IDE Study at The Aesthetic Meeting 2024. The study, which focuses on breast aesthetics and reconstruction, showed high patient compliance and low complication rates over four years. Dr. Caroline Glicksman presented the data, highlighting the consistency of clinical results and the potential for Motiva implants to set a new standard in breast implants in the U.S. The Motiva Implant PMA is currently under FDA review, with the implants not yet approved for commercial distribution in the United States.
May 02, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Establishment Labs Holdings Inc. (NASDAQ:ESTA) shared positive four-year results from the Motiva US IDE Study, indicating high patient compliance and low complication rates. The data was presented by Dr. Caroline Glicksman at The Aesthetic Meeting 2024, emphasizing the potential for Motiva implants to become a new standard in the U.S. breast implant market. The Motiva Implant PMA is under FDA review, with the product not yet approved for commercial distribution in the U.S.
The positive results from the Motiva US IDE Study could significantly impact ESTA's market position and future revenue potential, especially if the FDA approves the Motiva implants for commercial distribution in the U.S. The high patient compliance and low complication rates presented are likely to be viewed positively by investors, potentially leading to an increase in ESTA's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100